Morgan, E., Symons, S., Heyn, C., Carrera, P., Keith, J., Mainprize, T., . . . Perry, J. (2015). NIMG-51 T1-HYPERINTENSE LESIONS AS A PREDICTOR OF SURVIVAL IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ON BEVACIZUMAB. Neuro Oncol.
Style de citation ChicagoMorgan, Erin, et al. "NIMG-51 T1-HYPERINTENSE LESIONS AS A PREDICTOR OF SURVIVAL IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ON BEVACIZUMAB." Neuro Oncol 2015.
Style de citation MLAMorgan, Erin, et al. "NIMG-51 T1-HYPERINTENSE LESIONS AS A PREDICTOR OF SURVIVAL IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ON BEVACIZUMAB." Neuro Oncol 2015.
Attention : ces citations peuvent ne pas être correctes à 100%.